|
FR2492258A1
(fr)
|
1980-10-17 |
1982-04-23 |
Pharmindustrie |
Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
GB8504025D0
(en)
|
1985-02-16 |
1985-03-20 |
Biopharm Ltd |
Hyaluronidase
|
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
AU7873187A
(en)
|
1986-08-08 |
1988-02-24 |
University Of Minnesota |
Method of culturing leukocytes
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US7479269B2
(en)
|
1988-11-23 |
2009-01-20 |
Genetics Institute, Llc |
Methods for selectively enriching TH1 and TH2 cells
|
|
EP0401384B1
(en)
|
1988-12-22 |
1996-03-13 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
|
ATE176924T1
(de)
|
1988-12-23 |
1999-03-15 |
Genentech Inc |
Verfahren zur herstellung von menschlicher dnase
|
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5126132A
(en)
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
|
US5177017A
(en)
|
1990-03-22 |
1993-01-05 |
Trigen, Inc. |
Molecular cloning of the genes responsible for collagenase production from Clostridium histolyticum
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
GB9014932D0
(en)
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
DE69232137T2
(de)
|
1991-11-25 |
2002-05-29 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
JPH05244982A
(ja)
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化ｂ−ｂ１０
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5279823A
(en)
|
1992-06-08 |
1994-01-18 |
Genentech, Inc. |
Purified forms of DNASE
|
|
ATE240394T1
(de)
|
1992-10-23 |
2003-05-15 |
Immunex Corp |
Methoden zur herstellung löslicher, oligomerer proteine
|
|
US5593877A
(en)
|
1993-03-11 |
1997-01-14 |
The Rockefeller University |
Nucleic acid and recombinant production of vespid venom hyaluronidase
|
|
US5422261A
(en)
|
1993-04-16 |
1995-06-06 |
Baxter International Inc. |
Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
|
|
AU6816194A
(en)
|
1993-04-20 |
1994-11-08 |
Robinson, William S. |
Methods and materials for treatment of individuals infected with intracellular infectious agents
|
|
WO1994026290A1
(en)
*
|
1993-05-07 |
1994-11-24 |
Immunex Corporation |
Cytokine designated 4-1bb ligand and human receptor that binds thereto
|
|
US5942607A
(en)
*
|
1993-07-26 |
1999-08-24 |
Dana-Farber Cancer Institute |
B7-2: a CTLA4/CD28 ligand
|
|
GB9317380D0
(en)
|
1993-08-20 |
1993-10-06 |
Therexsys Ltd |
Transfection process
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
|
US5691188A
(en)
|
1994-02-14 |
1997-11-25 |
American Cyanamid Company |
Transformed yeast cells expressing heterologous G-protein coupled receptor
|
|
DE4447484C2
(de)
|
1994-04-08 |
1997-07-17 |
Deutsches Krebsforsch |
Mittel zur Hemmung von Apoptose
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
AU2946295A
(en)
|
1994-06-27 |
1996-01-19 |
Johns Hopkins University, The |
Targeted gene delivery system
|
|
US5908635A
(en)
|
1994-08-05 |
1999-06-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for the liposomal delivery of nucleic acids
|
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
ES2185770T3
(es)
|
1995-04-08 |
2003-05-01 |
Lg Chemical Ltd |
Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US5989888A
(en)
|
1996-01-24 |
1999-11-23 |
Roche Diagnostics Corporation |
Purified mixture of collagenase I, collagenase II and two other proteases
|
|
US6391607B1
(en)
|
1996-06-14 |
2002-05-21 |
Genentech, Inc. |
Human DNase I hyperactive variants
|
|
ATE386809T1
(de)
|
1996-08-02 |
2008-03-15 |
Bristol Myers Squibb Co |
Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
|
|
AU722624B2
(en)
|
1996-09-06 |
2000-08-10 |
Trustees Of The University Of Pennsylvania, The |
An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
|
|
RU2192281C2
(ru)
|
1996-10-11 |
2002-11-10 |
Бристол-Маерс Сквибб Компани |
Способы и композиции для иммуномодуляции
|
|
US6123938A
(en)
|
1996-10-17 |
2000-09-26 |
The Regents Of The University Of California |
Human urinary hyaluronidase
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6489458B2
(en)
|
1997-03-11 |
2002-12-03 |
Regents Of The University Of Minnesota |
DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
|
|
US7118742B2
(en)
|
1997-07-07 |
2006-10-10 |
La Jolla Institute For Allergy And Immunology |
Ligand for herpes simplex virus entry mediator and methods of use
|
|
US6475994B2
(en)
|
1998-01-07 |
2002-11-05 |
Donald A. Tomalia |
Method and articles for transfection of genetic material
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
ES2315008T5
(es)
|
1998-02-24 |
2012-03-06 |
Sisters Of Providence In Oregon |
Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral.
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
WO2000071150A1
(en)
|
1999-05-20 |
2000-11-30 |
Human Genome Sciences, Inc. |
Tumor necrosis factor receptor 5
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
|
AUPQ755300A0
(en)
*
|
2000-05-17 |
2000-06-08 |
Monash University |
Immune potentiating compositions
|
|
US6627442B1
(en)
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
|
ES2382636T3
(es)
|
2000-10-31 |
2012-06-12 |
Surmodics Pharmaceuticals, Inc. |
Método para producir composiciones para la administración mejorada de moléculas bioactivas
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
HUP0600342A3
(en)
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
|
WO2003057171A2
(en)
*
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
EA200401325A1
(ru)
|
2002-04-09 |
2005-04-28 |
Киова Хакко Когио Ко., Лтд. |
Клетки с модифицированным геномом
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
CA2489004C
(en)
|
2002-06-13 |
2013-01-08 |
Crucell Holland B.V. |
Agonistic binding molecules to the human ox40 receptor
|
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
WO2004003142A2
(en)
|
2002-06-28 |
2004-01-08 |
Xcyte Therapies, Inc. |
Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
|
PL375144A1
(en)
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
AU2003265948B8
(en)
|
2002-09-06 |
2009-09-03 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
AU2003271904B2
(en)
|
2002-10-09 |
2009-03-05 |
Adaptimmune Limited |
Single chain recombinant T cell receptors
|
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
ES2532399T3
(es)
|
2003-03-05 |
2015-03-26 |
Halozyme, Inc. |
Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden
|
|
CN101120083B
(zh)
|
2003-10-08 |
2013-03-27 |
威尔森沃尔夫制造公司 |
利用透气性材料进行细胞培养的方法及装置
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US20050249723A1
(en)
|
2003-12-22 |
2005-11-10 |
Xencor, Inc. |
Fc polypeptides with novel Fc ligand binding sites
|
|
CA2552788C
(en)
|
2004-01-12 |
2013-09-24 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
US20050177518A1
(en)
|
2004-02-10 |
2005-08-11 |
Brown Collie D. |
Electronic funds transfer and electronic bill receipt and payment system
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
DE102004014983A1
(de)
|
2004-03-26 |
2005-10-20 |
Univ Stuttgart |
Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
DK1765860T3
(da)
|
2004-05-19 |
2009-03-09 |
Immunocore Ltd |
Ny-ESO-T.cellereceptor med höj affinitet
|
|
AU2005250408B2
(en)
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
AU2005302459A1
(en)
|
2004-10-29 |
2006-05-11 |
University Of Southern California |
Combination cancer immunotherapy with co-stimulatory molecules
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
DK2650020T3
(en)
|
2005-05-06 |
2017-01-16 |
Providence Health & Services - Oregon |
Trimeric OX40 immunoglobulin fusion protein and methods for applications.
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
US8206702B2
(en)
|
2005-12-21 |
2012-06-26 |
Sentoclone International Ab |
Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
|
|
US8007785B2
(en)
|
2005-12-21 |
2011-08-30 |
Sentoclone International Ab |
Method for treating colon cancer with tumour-reactive T-lymphocytes
|
|
US8211424B2
(en)
|
2005-12-21 |
2012-07-03 |
Sentoclone International Ab |
Method for treating malignant melanoma
|
|
EP1966370B1
(en)
|
2005-12-21 |
2013-02-20 |
SentoClone International AB |
Method for obtaining T-lymphocytes
|
|
TWI466269B
(zh)
|
2006-07-14 |
2014-12-21 |
Semiconductor Energy Lab |
非揮發性記憶體
|
|
EP1894940A1
(en)
|
2006-08-28 |
2008-03-05 |
Apogenix GmbH |
TNF superfamily fusion proteins
|
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
US20100136030A1
(en)
|
2007-02-27 |
2010-06-03 |
Lamhamedi-Cherradi Salah-Eddine |
Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
US7951365B2
(en)
|
2007-06-27 |
2011-05-31 |
Deifiera Falun Ab |
Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
|
|
EP2176288B1
(en)
|
2007-07-10 |
2015-11-04 |
Apogenix GmbH |
Tnf superfamily collectin fusion proteins
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
DK2851374T3
(en)
|
2007-12-14 |
2017-06-19 |
Bristol Myers Squibb Co |
Binding molecules to the human OX40 receptor
|
|
US8629098B2
(en)
*
|
2008-01-15 |
2014-01-14 |
Yale University |
Compositions and methods for adoptive and active immunotherapy
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
EP2540740B1
(en)
|
2008-06-17 |
2014-09-10 |
Apogenix GmbH |
Multimeric TNF receptors
|
|
DK2604693T3
(en)
|
2008-07-21 |
2016-05-30 |
Apogenix Gmbh |
Single-chain TNFSF molecules
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
WO2014085437A2
(en)
|
2012-11-27 |
2014-06-05 |
The Johns Hopkins University |
Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
|
|
US20150320798A1
(en)
|
2012-11-27 |
2015-11-12 |
The Johns Hopkins University |
Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
JP5844158B2
(ja)
|
2009-01-09 |
2016-01-13 |
アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ |
三量体形成融合タンパク質
|
|
WO2010088160A1
(en)
*
|
2009-01-28 |
2010-08-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
|
AU2010241864B2
(en)
|
2009-04-30 |
2014-02-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible interleukin-12
|
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
Anti-gitr antibodies
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
US8809050B2
(en)
|
2009-12-08 |
2014-08-19 |
Wilson Wolf Manufacturing |
Methods of cell culture for adoptive cell therapy
|
|
US20130115617A1
(en)
|
2009-12-08 |
2013-05-09 |
John R. Wilson |
Methods of cell culture for adoptive cell therapy
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
EP3165540A1
(en)
|
2010-04-13 |
2017-05-10 |
Celldex Therapeutics, Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
US9783578B2
(en)
|
2010-06-25 |
2017-10-10 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
SMT201700185T1
(it)
|
2010-08-23 |
2017-05-08 |
Univ Texas |
Anticorpi anti-ox40 e metodi di uso degli stessi
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
ES2385239B1
(es)
|
2010-09-30 |
2013-06-19 |
Proteos Biotech S.L.U. |
Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
|
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012129201A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
EP2697367B1
(en)
|
2011-04-13 |
2018-12-19 |
Immunicum AB |
Method for proliferation of antigen-specific t cells
|
|
CN103732238A
(zh)
|
2011-06-08 |
2014-04-16 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的治疗性化合物
|
|
US20140234320A1
(en)
|
2011-06-20 |
2014-08-21 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
JP6240600B2
(ja)
|
2011-07-24 |
2017-11-29 |
キュアテク リミテッド |
ヒト化免疫モノクローナル抗体の変異体
|
|
CA2845810C
(en)
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
WO2013040557A2
(en)
|
2011-09-16 |
2013-03-21 |
The Trustees Of The University Of Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
|
AU2012324644B2
(en)
|
2011-10-21 |
2014-08-28 |
Cell Medica Limited |
Device for the aseptic expansion of cells
|
|
WO2013070468A1
(en)
*
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
WO2013132317A1
(en)
|
2012-03-07 |
2013-09-12 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
|
WO2013134464A1
(en)
*
|
2012-03-07 |
2013-09-12 |
Children's Medical Center Corporation |
Tissue constructs and uses thereof
|
|
AU2013239366A1
(en)
|
2012-03-29 |
2014-10-16 |
Aurigene Discovery Technologies Limited |
Immunomodulating cyclic compounds from the BC loop of human PD1
|
|
SG11201407226WA
(en)
|
2012-05-18 |
2014-12-30 |
Wolf Wilson Mfg Corp |
Improved methods of cell culture for adoptive cell therapy
|
|
CN104411819B
(zh)
|
2012-06-11 |
2019-05-10 |
威尔逊沃夫制造公司 |
用于过继细胞疗法的改进的细胞培养方法
|
|
US9382329B2
(en)
*
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
EP3628322A1
(en)
|
2013-03-01 |
2020-04-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer
|
|
RU2671897C2
(ru)
|
2013-03-01 |
2018-11-07 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
|
|
EP2970907B1
(en)
|
2013-03-14 |
2020-01-01 |
The Johns Hopkins University |
Nanoscale artificial antigen presenting cells
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
SMT201800503T1
(it)
|
2013-03-18 |
2018-11-09 |
Janssen Pharmaceuticals Inc |
Anticorpi anti-cd (ox40) umanizzati e loro usi
|
|
CN118562610A
(zh)
|
2013-06-24 |
2024-08-30 |
威尔逊沃夫制造公司 |
用于透气性细胞培养过程的封闭系统装置和方法
|
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
JP6616295B2
(ja)
|
2013-07-15 |
2019-12-04 |
アメリカ合衆国 |
抗ヒトパピローマウイルス抗原ｔ細胞の調製方法
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
HRP20181052T1
(hr)
|
2013-09-06 |
2018-09-07 |
Aurigene Discovery Technologies Limited |
Derivati 1,2,4-oksadiazola kao imunomodulatori
|
|
SI3041828T1
(sl)
|
2013-09-06 |
2018-10-30 |
Aurigene Discovery Technologies Limited |
1,3,4-oksadiazolni in 1,3,4-tiadiazolni derivati kot imunomodulatorji
|
|
WO2015036927A1
(en)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
|
EA034666B1
(ru)
|
2013-09-13 |
2020-03-04 |
Бейджин Свитзерланд Гмбх |
Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
|
|
WO2015039100A1
(en)
|
2013-09-16 |
2015-03-19 |
The Trustees Of The University Of Pennsylvania |
Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
|
|
WO2015047860A1
(en)
|
2013-09-27 |
2015-04-02 |
Acclarent, Inc. |
Enhanced gripping features for nasal and paranasal sinus systems
|
|
JP2016539929A
(ja)
*
|
2013-10-25 |
2016-12-22 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
免疫療法のためのポリクローナルγδＴ細胞
|
|
AU2014364606A1
(en)
|
2013-12-17 |
2016-07-07 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
|
EP3686219A1
(en)
|
2014-02-04 |
2020-07-29 |
Pfizer Inc |
Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
|
|
JP2017511375A
(ja)
|
2014-03-20 |
2017-04-20 |
エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド |
養子細胞療法のための腫瘍浸潤リンパ球
|
|
WO2015157636A1
(en)
|
2014-04-10 |
2015-10-15 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
US11173146B2
(en)
|
2014-04-25 |
2021-11-16 |
The Regents Of The University Of California |
Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use
|
|
DK3152569T3
(da)
*
|
2014-06-05 |
2020-08-17 |
Aimm Therapeutics Bv |
Midler og fremgangsmåder til bestemmelse af t-cellegenkendelse
|
|
AU2015273501B2
(en)
|
2014-06-11 |
2021-01-21 |
Polybiocept Gmbh |
Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
|
|
US9687510B2
(en)
|
2014-09-04 |
2017-06-27 |
The Johns Hopkins University |
Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
|
|
AU2014407539B2
(en)
|
2014-10-02 |
2020-10-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
|
|
EP3034092A1
(en)
|
2014-12-17 |
2016-06-22 |
Université de Lausanne |
Adoptive immunotherapy for treating cancer
|
|
IL253208B2
(en)
|
2015-01-04 |
2023-03-01 |
Protalix Ltd |
Converted DNase and its uses
|
|
US20180044429A1
(en)
|
2015-03-09 |
2018-02-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
US10544392B2
(en)
|
2015-05-01 |
2020-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
FR3040396A1
(fr)
|
2015-06-30 |
2017-03-03 |
Chu Nantes |
Procede de cryoconservation de lymphocytes infiltrant la tumeur
|
|
FR3038324B1
(fr)
|
2015-06-30 |
2020-10-30 |
Lab Francais Du Fractionnement |
Procede de cryoconservation de cellules a visee therapeutique
|
|
WO2017048614A1
(en)
|
2015-09-15 |
2017-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
|
|
SG11201803330WA
(en)
|
2015-10-22 |
2018-05-30 |
Juno Therapeutics Gmbh |
Methods for culturing cells and kits and apparatus for same
|
|
CN108463547A
(zh)
|
2015-10-28 |
2018-08-28 |
生命技术股份公司 |
通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群
|
|
KR20190037243A
(ko)
|
2016-06-28 |
2019-04-05 |
지니우스 바이오테크놀로지 인코포레이티드 |
면역치료를 위한 티 세포 조성물
|
|
CN106244538A
(zh)
|
2016-08-04 |
2016-12-21 |
英普乐孚生物技术(上海)有限公司 |
一种恶性腹水来源的til细胞的分离培养方法
|
|
MX2019004707A
(es)
|
2016-10-26 |
2019-08-12 |
Iovance Biotherapeutics Inc |
Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
|
|
TWI788307B
(zh)
*
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
WO2018102761A1
(en)
|
2016-12-02 |
2018-06-07 |
City Of Hope |
Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
|
|
CN106591232A
(zh)
|
2017-01-04 |
2017-04-26 |
安徽安龙基因医学检验所有限公司 |
一种高效的pd‑1‑cd8+t细胞的培养方法
|
|
SG11201908271WA
(en)
|
2017-03-14 |
2019-10-30 |
Juno Therapeutics Inc |
Methods for cryogenic storage
|
|
CN107384867B
(zh)
|
2017-08-04 |
2020-09-11 |
北京世纪劲得生物技术有限公司 |
一种肿瘤组织til细胞制备方法及专用培养基
|
|
CA3134144A1
(en)
*
|
2019-03-29 |
2020-10-08 |
Myst Therapeutics, Llc |
Ex vivo methods for producing a t cell therapeutic and related compositions and methods
|
|
AU2020355025A1
(en)
*
|
2019-09-23 |
2022-04-07 |
Regents Of The University Of Minnesota |
Genetically-edited immune cells and methods of therapy
|